Expert Discusses Immunotherapy Advances in Head and Neck Cancer – OncLive
OncLive |
Expert Discusses Immunotherapy Advances in Head and Neck Cancer
OncLive “Regarding the responsiveness of immunotherapy versus the responsiveness of standard-of-care chemotherapy, platinum-based doublets with cetuximab have response rates of 40% and PD-1 inhibitors have response rates of 18%. For symptomatic patients … |
